Bouda GC, et al. - The results of an intensive polychemotherapy regimen for Burkitt lymphoma (BL) were determined in sub-Saharan African pediatric centers. Researchers analyzed 400 children [Median age: 7.3 years; gender ratio: 1.9:1 (male:female)] with advanced-stage BL (stages II bulky, III, and IV) who underwent treatment with the GFAOP–Lymphomes Malins B (GFALMB) 2009 protocol in 7 centers between April 2009 and September 2015. Treatment regimen comprised a prephase with cyclophosphamide followed by 2 induction courses (cyclophosphamide, vincristine, prednisone, high-dose methotrexate [HDMTX]), 2 consolidation courses (cytarabine, HDMTX), and a maintenance phase only for stage IV. At the dose of 3 g/m², HDMTX was provided. Among 400 analyzed patients: 7% had stage II bulky, 76% stage III, and 17% stage IV disease. The whole protocol treatment was received by a total of 221 patients and complete remission (CR) was observed in 195 achieved, in 11 of them following second-line treatment. They observed improved patients' survival with the GFA-LMB2009 protocol. A strong prognostic factor was early dose intensity of treatment. Findings emphasize improving supportive care and reducing loss to follow-up as crucial. Findings suggest that, although many difficulties could be encountered, the cure can be achieved in a significant percentage of children with Burkitt lymphoma in sub-Saharan countries.